Lasica, Masa

Anderson, Mary A

Boussioutas, Alex

Gregory, Gareth P

Hamad, Nada

Manos, Kate

McKelvie, Penny

Ng, Michael

Campbell, Belinda

Palfreyman, Emma

Salvaris, Ross

Weinkove, Robert

Wight, Joel

Opat, Stephen

Tam, Constantine

2024-06-01

Marginal zone lymphomas (MZLs) are a rare, indolent group of non-Hodgkin lymphomas with different diagnostic, genetic and clinical features and therapeutic implications. The most common is extranodal MZL of mucosa-associated lymphoid tissue, followed by splenic MZL and nodal MZL. Patients with MZL generally have good outcomes with long survival rates but frequently have a relapsing/remitting course requiring several lines of therapy. The heterogeneous presentation and relapsing course present the clinician with several diagnostic and therapeutic challenges. This position statement presents evidence-based recommendations in the setting of Australia and New Zealand.

Department of Clinical Haematology, St Vincent's Hospital, Melbourne, Victoria, Australia.

The University of Melbourne, Melbourne, Victoria, Australia.

Department of Clinical Haematology, Royal Melbourne Hospital and The Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Division of Blood Cells and Blood Cancer, Walter and Eliza Hall Institute, Melbourne, Victoria, Australia.

Department of Gastroenterology, Alfred Health, Melbourne, Victoria, Australia.

Monash University, Melbourne, Victoria, Australia.

The Alfred, Melbourne, Victoria, Australia.

Familial Cancer Clinic, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.

Monash Haematology, Monash Health, Melbourne, Victoria, Australia.

Department of Haematology, St Vincent's Hospital, Sydney, New South Wales, Australia.

Department of Haematology, Flinders Medical Centre, Adelaide, South Australia, Australia.

Department of Anatomical Pathology, St Vincent's Hospital, Melbourne, Victoria, Australia.

GenesisCare St Vincent's Hospital, Melbourne, Victoria, Australia.

Department of Radiation Oncology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Victoria, Australia.

Department of Clinical Pathology, University of Melbourne, Melbourne, Victoria, Australia.

Department of Haematology, Royal Darwin Hospital, Darwin, Northern Territory, Australia.

Department of Haematology, Sir Charles Gairdner Hospital, Perth, Western Australia, Australia.

School of Medicine, University of Western Australia, Perth, Western Australia, Australia.

Te Rerenga Ora Blood & Cancer Centre, Te Whatu Ora Health New Zealand Capital, Coast & Hutt Valley, Wellington, New Zealand.

Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.

Department of Pathology and Molecular Medicine, University of Otago Wellington, Wellington, New Zealand.

Department of Haematology and Bone Marrow Transplantation, Townsville University Hospital, Townsville, Queensland, Australia.

School of Medicine, James Cook University, Townsville, Queensland, Australia.

Monash Haematology, Monash Health, Melbourne, Victoria, Australia.

School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia.

Haematology Department, Alfred Hospital, Melbourne, Victoria, Australia.

Central Clinical School, Monash University, Melbourne, Victoria, Australia.

Intern Med J . 2024 Jun;54(6):1017-1030. doi: 10.1111/imj.16390.

1445-5994

0000-0001-7971-4003

0000-0002-4170-0682

0000-0001-7929-1450

0000-0003-1053-5503

0000-0002-9759-5017

https://pubmed.ncbi.nlm.nih.gov/38881453/?otool=iaurydwlib

https://hdl.handle.net/10137/13408

Australasian Lymphoma Alliance

marginal zone lymphoma

practice statement

treatment

Humans

Lymphoma, B-Cell, Marginal Zone

Australia

New Zealand

Consensus

Marginal zone lymphomas: a consensus practice statement from the Australasian Lymphoma Alliance.

Journal Article

Publication